Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Sagimet Biosciences (Nasdaq: SGMT) announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A fireside chat at 2:00 p.m. ET will be webcast live and archived for 90 days on Sagimet’s website.
Sagimet Biosciences (Nasdaq: SGMT) reported Q1 2026 results and key updates. The company completed a $175M equity financing in April 2026 and held $104.5M in cash, cash equivalents and marketable securities as of March 31, 2026.
According to Sagimet, the combined cash runway is expected to fund acne programs through 2028, including a planned Phase 3 denifanstat trial in moderate to severe acne in the U.S., targeted to start in H2 2026. An ongoing first-in-human Phase 1 trial of FASN inhibitor TVB-3567 supports plans for a Phase 2 acne trial in H2 2026. Q1 2026 R&D expense fell to $7.0M from $15.3M, and net loss narrowed to $10.7M from $18.2M year over year.
Sagimet Biosciences (Nasdaq: SGMT) will present new preclinical mechanism-of-action data on its FASN inhibitors for acne at the Society for Investigative Dermatology meeting in Chicago on May 15, 2026.
The data link reduced sebum-related lipids in human sebocytes to FASN inhibition and support a planned U.S. Phase 3 acne trial in 2H 2026.
Sagimet Biosciences (Nasdaq: SGMT) priced an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, for gross proceeds of approximately $175.0 million. The offering is expected to close on or about April 28, 2026, subject to customary conditions.
Proceeds are intended to fund a Phase 3 denifanstat acne trial, advance TVB-3567 to Phase 2 topline results, support a topical FASN inhibitor IND submission, and provide general corporate funding; the company expects cash to fund acne programs through 2028.
Sagimet (NASDAQ: SGMT) provided strategic and corporate updates on April 27, 2026, focusing on dermatology advancement and portfolio prioritization.
The company plans a U.S. Phase 3 trial of oral denifanstat for moderate to severe acne in the second half of 2026, subject to IND clearance, and reported positive topline safety results from a China Phase 3 open-label trial (n=240) of 50 mg once-daily denifanstat. Ongoing programs include a first-in-human Phase 1 trial of FASN inhibitor TVB-3567, a completed Phase 1 PK study for denifanstat+resmetirom, and a pause on further MASH development until non-dilutive funding is secured. New CMO appointment and an investor KOL webcast on April 30, 2026 were announced.
Sagimet Biosciences (Nasdaq: SGMT) appointed Andreas Grauer, MD as Chief Medical Officer effective April 20, 2026; prior CMO Eduardo Bruno Martins retired and will serve as an external scientific advisor.
Dr. Grauer has 20+ years of global clinical development experience. Sagimet approved an inducement stock option valued at $1,340,000 (Black Scholes value) granted April 20, 2026, with a ten-year term and four-year vesting; exercise price equals the closing Nasdaq price on April 20, 2026.
Sagimet (Nasdaq: SGMT) will present Phase 2b FASCINATE-2 data at the Fueling MASH Keystone Symposium April 12-15, 2026 in Vancouver.
In denifanstat-treated MASH patients, histological responders showed significant reductions in glycine- and taurine-conjugated bile acids at 26 weeks. Sagimet also granted an inducement award of 9,600 stock options on April 3, 2026 to a new hire; options vest over four years and carry a ten-year term.
Sagimet Biosciences (Nasdaq: SGMT) reported 2025 year-end results and clinical progress on March 11, 2026. Key items: $113.1M cash balance, completion of a Phase 1 PK trial of denifanstat plus resmetirom with no safety signals, an exclusive global license to TAPI resmetirom API, and NMPA acceptance of an NDA for denifanstat in acne.
Planned near-term milestones include a Phase 2 proof-of-concept trial in F4 MASH in 2H 2026 and anticipated Phase 2 acne studies for TVB-3567 in 2026.
Sagimet Biosciences (Nasdaq: SGMT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 2 (Boston), Leerink on March 9 (Miami) and Citizens Life Sciences on March 10 (Miami).
TD Cowen and Leerink fireside chats will be webcast and archived for 90 days on the company's investor site.
Sagimet Biosciences (Nasdaq: SGMT) announced management will participate in two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 at 10:00 AM ET and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 9:20 AM ET.
Both fireside chats will be webcast in the Investors & Media section at www.sagimet.com, with archived replays available for 90 days after each live event.